Literature DB >> 3656605

Cholesterol embolization syndrome. Occurrence after intravenous streptokinase therapy for myocardial infarction.

M W Schwartz1, G B McDonald.   

Abstract

Two patients developed the cholesterol embolization syndrome after coronary angiography and intravenous streptokinase therapy for acute myocardial infarction. Clinical manifestations included cyanosis, ulcers, gangrene of the hands and feet, myalgias, intestinal infarction, eosinophilia, and renal failure. One patient died; one has survived with chronic renal failure. Streptokinase therapy may expose atheromatous plaques to the circulation by lysing platelet-fibrin thrombi.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3656605     DOI: 10.1001/jama.258.14.1934

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  'Spontaneous' cholesterol embolisation syndrome after successful prehospital thrombolysis for acute myocardial infarction.

Authors:  S A M Said; A Wester; R M L Brouwer; S H J Monnink; W A H Koning-Mulder; R A I de Vos; J van Baarlen
Journal:  Neth Heart J       Date:  2005-06       Impact factor: 2.380

2.  Acute renal failure following intravenous streptokinase infusion for acute myocardial infarction.

Authors:  Y Birnbaum; B Strasberg; E Rechavia; Y Neuman; B Stahl
Journal:  West J Med       Date:  1993-04

3.  Investigation of the thoracic aorta in cholesterol embolism by transoesophageal echocardiography.

Authors:  E Ferrari; B Taillan; E Drai; P Morand; M Baudouy
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

Review 4.  Cholesterol embolisation after thrombolytic therapy.

Authors:  J C Blankenship
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

5.  Microembolism from aortic aneurysm and ventricular thrombus: a complication of intravenous streptokinase.

Authors:  J S Abraham; M Wilson; V Scripcariu; P C Barnes; R W Marcuson
Journal:  Postgrad Med J       Date:  1994-10       Impact factor: 2.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.